What is HC Wainwright's Forecast for ENTA Q3 Earnings?

Key Points

• HC Wainwright has projected Enanta Pharmaceuticals to report ($1.22) earnings per share for Q3 2025, with a full-year earnings estimate of ($4.65) per share.
• The biotech company currently holds a Buy rating from HC Wainwright and has an adjusted target price of $20.00 on its stock.
• Enanta Pharmaceuticals has a consensus rating of Moderate Buy among analysts, with a current average target price of $18.50.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Enanta Pharmaceuticals in a report issued on Monday, July 28th. HC Wainwright analyst B. Folkes anticipates that the biotechnology company will post earnings per share of ($1.22) for the quarter. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals' Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($4.69) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($3.65) EPS, FY2028 earnings at ($2.35) EPS and FY2029 earnings at ($2.35) EPS.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative return on equity of 79.83% and a negative net margin of 149.57%.

A number of other research analysts have also commented on ENTA. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. JMP Securities lifted their price objective on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a report on Tuesday, June 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.50.

Enanta Pharmaceuticals Stock Down 6.2%

Shares of ENTA traded down $0.47 during midday trading on Wednesday, reaching $7.11. 195,593 shares of the stock were exchanged, compared to its average volume of 177,921. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $14.21. The firm has a 50 day simple moving average of $7.25 and a 200-day simple moving average of $6.36. The company has a market cap of $151.99 million, a price-to-earnings ratio of -1.57 and a beta of 0.88.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. CWM LLC grew its stake in Enanta Pharmaceuticals by 22.1% in the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company's stock valued at $162,000 after acquiring an additional 3,879 shares during the period. Farther Finance Advisors LLC raised its holdings in Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 5,779 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $88,000. Goldman Sachs Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 5.3% during the first quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company's stock worth $720,000 after purchasing an additional 6,549 shares during the period. Finally, Acadian Asset Management LLC increased its stake in shares of Enanta Pharmaceuticals by 2.1% during the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company's stock worth $4,782,000 after purchasing an additional 17,613 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.